ArticleScientific reports2025
In vivo antitumor activity of doxorubicin loaded on chitosan functionalized Pb
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Versatile SI-ATRP Growth of Methacrylate Brushes on Superparamagnetic Iron Oxide Nanoparticles Enables Methotrexate-Mediated Antineoplastic Activity in MCF-7 Cells.Pharmaceutics · 2026Article
- Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.Breast cancer research : BCR · 2026Review
- Modulation of oxidative stress and P53/PCNA signaling by glucosodiene-loaded nanoferrites (GLONF) in ehrlich solid tumor-induced hepatotoxicity.Scientific reports · 2026Article
- Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoscale materials can improve cancer treatment by safely and efficiently delivering chemotherapeutic drugs. This study was designated to load the anticancer drug doxorubicin (DOX) into chitosan-coated Pb2Mn2Fe12O22 magnetic nanoparticles (CT-MNPs) and compare their physicochemical and biological effects with free drug, in addition to the therapeutic role of DOX-CT-MNPs to acting efficaciously in restraint of cancer cells growth and evolution using Ehrlich solid tumor model (EST). Forty female mice were randomly and equally split into four groups (EST; EST + Free DOX; EST + CT-MNPs; and EST + DOX-CT-MNPs). Our findings show that treating EST with DOX, either free or loaded on CT-MNPs, inhibits tumour growth by producing oxidative stress, disrupting the antioxidant system, activating apoptosis, and arresting the cell cycle. Furthermore, DOX loaded on CT-MNPs had greater anticancer activity than DOX in its free form. This highlights the potential advantages of CT-MNPs in tumour therapy and drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.